


PHARMACEUTICAL 2021

Enochian Biosciences Inc Rank 32 of 409





PHARMACEUTICAL 2021



Enochian Biosciences Inc Rank 32 of 409

The relative strengths and weaknesses of Enochian Biosciences Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Enochian Biosciences Inc compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 298% points. The greatest weakness of Enochian Biosciences Inc is the variable Revenues, reducing the Economic Capital Ratio by 31% points.

The company's Economic Capital Ratio, given in the ranking table, is 144%, being 499% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	8,941
Cost of Goods Sold	0
Intangible Assets	11,717
Liabilities, Current	1,335
Liabilities, Non-Current	1,532
Other Assets	156,665
Other Compr. Net Income	0
Other Expenses	109
Other Liabilities	8,963
Other Net Income	507
Property and Equipment	778
Research and Development	4,694
Revenues	0
Selling, General and Administrative Expense	7,121

Output Variable	Value in 1000 USD
Assets	178,102
Liabilities	11,830
Expenses	11,924
Stockholders Equity	166,272
Net Income	-11,416
Comprehensive Net Income	-11,416
Economic Capital Ratio	144%